NCT03572829 is a Phase 2 clinical trial of Aprepitant in Vomiting, sponsored by Chinese Academy of Medical Sciences.

Who is sponsoring NCT03572829?

NCT03572829 is sponsored by Chinese Academy of Medical Sciences.

What drugs are being tested in NCT03572829?

Interventions in NCT03572829: Aprepitant.

What condition does NCT03572829 study?

NCT03572829 studies Vomiting, Nausea Post Chemotherapy, Head Neck Cancer.

Is NCT03572829 still recruiting?

NCT03572829 is currently completed. Last updated 15 July 2020.

Last reviewed 2020-07-15 · How we verify

NCT03572829

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC

Completed Phase 2 Last updated 15 July 2020

What this trial tests

Phase 2 trial testing Aprepitant in Vomiting in 44 participants. Completed in 1 July 2020.

Timeline

1 March 2018

Primary endpoint
9 January 2020

1 July 2020

Quick facts

Lead sponsor	Chinese Academy of Medical Sciences
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	44
Start date	1 March 2018
Primary completion	9 January 2020
Estimated completion	1 July 2020
Sites	1 location across China

Drugs / interventions tested

Aprepitant (APREPITANT) — full drug profile →

Conditions studied

Vomiting — all drugs for Vomiting →
Nausea Post Chemotherapy — all drugs for Nausea Post Chemotherapy →
Head Neck Cancer — all drugs for Head Neck Cancer →

Sponsor

Chinese Academy of Medical Sciences — full company profile →

Who can join

Adults 18 to 80, any sex, with Vomiting or Nausea Post Chemotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and efficacy of aprepitant combined with ondansetron and dexamethasone to prevent nausea and vomiting induced by Intensity-modulated Radiotherapy (IMRT) cisplatin-chemotherapy regimen in locally advanced squamous cell carcinoma of head and neck

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Antiemetic prophylaxis for chemoradiotherapy-induced nausea and vomiting in locally advanced head and neck squamous cell carcinoma: a prospective phase II trial.
Wang Z, Liu W, Zhang J, Chen X, et al · · 2022 · cited 6× · PMID 35635557 · DOI 10.1007/s00066-022-01958-7
Antiemetic Prophylaxis for Chemoradiotherapy-induced Nausea and Vomiting (C-RINV) in Locally Advanced Head and Heck Squamous Cell Carcinoma: a Prospective Phase Ⅱ Trial
Wang Z, Liu W, Zhang J, Chen X, et al · · 2021 · DOI 10.21203/rs.3.rs-948378/v1
Antiemetic Prophylaxis for Chemoradiotherapy-Induced Nausea and Vomiting (C-RINV) in Locally Advanced Head and Heck Squamous Cell Carcinoma (LA-HNSCC): A Prospective Phase Ⅱ Trial
Wang Z, Liu W, Zhang J, Chen X, et al · · 2021 · DOI 10.21203/rs.3.rs-645529/v1

Verify or expand the search:

Other trials of Aprepitant

Trials testing the same drug.

NCT07371728 — Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery · Phase 4 · not yet recruiting
NCT04606264 — Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data · Phase 3 · completed
NCT05772676 — The Effect of Aprepitant Reducing Postoperative Nausea and Vomiting · Phase 4 · unknown
NCT05632224 — Postoperative Nausea and Vomiting in Laparoscopic Abdominal Surgery · Phase 4 · unknown
NCT04912271 — Granisetron Transdermal Patch for Prophylaxis of Delayed CINV · Phase 3 · unknown

Other recruiting trials for Vomiting

Currently open trials in the same condition.

NCT07208305 — Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting · Phase 3 · recruiting
NCT06954935 — Periorbital Massage for Nausea and Vomiting After Laparoscopic Surgery · NA · recruiting
NCT06777758 — Comparison of Remimazolam and Propofol in Endoscopic Examinations and Treatments · Phase 4 · recruiting
NCT06704698 — Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery · NA · recruiting
NCT06582576 — Mechanisms of Action for the Enterra Medical Gastric Electrical Stimulator · recruiting

Other Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT05522894 — AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC · Phase 2 · unknown
NCT05499715 — A Phase I Clinical Study to Evaluate the Safety, the Tolerability, the Pharmacokinetic Characteristics and the Efficacy · Phase 1 · unknown
NCT05484024 — Short-course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer · Phase 2, PHASE3 · not yet recruiting
NCT05543070 — Low-dose Radiotherapy in iNHL · Phase 2 · unknown
NCT05460403 — Adjuvant Radiotherapy for Patients With Esophageal Squamous Cell Carcinoma After R0 Resection · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03572829 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese Academy of Medical Sciences
Last refreshed: 15 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03572829.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing